Recovery from an autoimmune inflammation of the brain may take three years or more, according to a study published in the November 20, 2024, online issue of Neurology®, the medical journal of the American Academy of Neurology.
The use of biologic and targeted therapies for children with juvenile idiopathic arthritis (JIA) surpassed more typical therapies in recent years, according to Rutgers Health researchers.
In APL Bioengineering, researchers employed analysis tools and machine learning algorithms to identify two genes linked to rheumatoid arthritis and osteoporosis that could serve as diagnostic tools and potential targets for treatments. Drawing from a large database of genetic information, they gathered dozens of sequenced genomes from people with rheumatoid arthritis and osteoporosis to look for any similarities, using recently developed computational methods to narrow down their search. They identified genes ATXN2L and MMP14 as significantly associated with the progression of both rheumatoid arthritis and osteoporosis.
Multiple sclerosis (MS) is a debilitating disease of the brain and spinal cord that impacts millions worldwide. In MS, the immune system mistakenly attacks the myelin sheath—a protective layer surrounding nerve cells in the nervous system. The loss of myelin, combined with ongoing inflammation, causes dysfunction and death of nerve cells, making the disability worse, such as difficulties with movement, coordination, and sensation. Treatments now focus on reducing attacks on myelin, but don’t address nerve-cell damage and death. But with $1 million from the National Multiple Sclerosis Society (NMSS), a research team co-led by Paul Tesar, the Dr. Donald and Ruth Weber Goodman Professor of Innovative Therapeutics and director of the Institute for Glial Sciences, and Ben Clayton, assistant professor and founding member of the Institute for Glial Sciences, both in the Department of Genetics and Genome Sciences at the Case Western Reserve University School of Medicine, will take a different
Researchers at WashU Medicine have found a process by which the brain guards against attack by the immune system. In mice with multiple sclerosis, such "guardian" proteins that train the immune system were drastically depleted, and replenishing them improved symptoms, according to a study in Nature.
A new intervention to help young people with chronic childhood arthritis overcome barriers to physical activity and mental wellbeing will be developed by University of South Australia researchers.
IgA nephropathy is an autoimmune kidney disease, and complement, a component of the innate immune system, plays a role in the condition’s pathogenesis. Investigators have developed and tested a novel gene therapy that enters kidney cells and enables them to block complement activation. The research will be presented at ASN Kidney Week 2024 October 23– 27.
IgA nephropathy (IgAN) is an autoimmune kidney disease driven by immune cells that express a protein called CD38 on their surface. A recent Phase 2 trial revealed that felzartamab, an investigational anti-CD38 monoclonal antibody, helps to reduce proteinuria and maintain patients’ kidney function. Investigators evaluated the molecular mechanisms underlying felzartamab’s potential efficacy in IgAN. The findings will be presented at ASN Kidney Week 2024 October 23– 27.
Scientists from Cleveland Clinic and Cornell University have designed a publicly-available software and web database to break down barriers to identifying key protein-protein interactions to treat with medication.
This feature profiles Parinaz Fathi, Ph.D., an early career researcher at NIBIB, leading an intramural research unit that develops miniature organ models to study immune-related conditions and evaluates the role of biological nanoparticles in autoimmune diseases and cancer. She also creates award-winning scientific art.
SciRhom GmbH, a biotech startup co-founded by Hospital for Special Surgery (HSS), recently secured a 63 million euro (US$70 million) Series A financing round to support the clinical development of its novel drug candidate, SR-878. The round was co-led by Andera Partners, Kurma Partners, Hadean Ventures, MIG Capital, and Wellington Partners, with participation from new investor Bayern Kapital and existing investors. This news follows the company’s recently received approval from Austrian regulatory authorities (BASG/AGES) required to commence its first-in-human Phase I clinical trial in Europe this fall.
The Autoimmune Association is proud to announce a new partnership with U.S. Olympic swimmer Paige Madden, a decorated athlete and champion in the pool, to amplify awareness of autoimmune diseases.
UC San Diego researchers discover two distinct molecular subtypes of Crohn’s disease using patient-derived organoids, opening the door to personalized treatment for the chronic inflammatory bowel disease.
PARAGON Study Shows NEUROMARK® Treatment Benefits Allergic and Nonallergic Rhinitis Patients
A phase 2 trial of a monoclonal antibody known as tulisokibart for moderate-to-severe ulcerative colitis (UC) showed promising results for those who have not responded to conventional inflammatory bowel disease (IBD) treatment. The results were reported Thursday, September 26, in The New England Journal of Medicine.
Rutgers Health researchers will enroll primary or secondary progressive multiple sclerosis (p-MS) patients to see if an engineered immune cell therapy can halt the progression of the autoimmune disease.
Starting patients with multiple sclerosis (MS) on aggressive treatment earlier may help prevent the development of paramagnetic rim lesions (PRL), areas of chronic brain inflammation that are linked to faster decline due to the disease, suggests new research presented at the 149th Annual Meeting of the American Neurological Association (ANA). People with MS who have PRLs tend to have greater brain atrophy and disability. Treatment for MS includes low-, moderate- or high-efficacy disease-modifying therapies (DMTs), such as monoclonal antibodies, immunomodulators and immunosuppressants. While high-efficacy DMTs have more side effects, previous research suggests they may help prevent PRLs from forming (unlike low- or moderate-efficacy DMTs), potentially outweighing the downsides. No currently available DMT has been shown to reduce existing PRLs.
La Jolla Institute for Immunology (LJI) has been selected as a spoke for the Investor Catalyst Hub, a regional hub of ARPANET-H, a nationwide health innovation network launched by the Advanced Research Projects Agency for Health (ARPA-H).
Scleroderma is a chronic autoimmune disease of women.Over time, people living with scleroderma develop progressive and irreversible scarring.Scarring, called fibrosis, effects the lungs, heart and kidneys, leading to poor quality of life, disability and a reduced life expectancy.
A computer model developed by UT Southwestern Medical Center researchers significantly enhances the ability of scientists to detect communication between cells, according to a new study published in Nature Methods.
RSS
Medicine keyboard_arrow_right
Sciencekeyboard_arrow_right
Life keyboard_arrow_right
Business keyboard_arrow_right
Journal News keyboard_arrow_right
By Location keyboard_arrow_right
Meetings, Grants, and Events keyboard_arrow_right